---
title: "Xiamen Amoytop Biotech Co., Ltd. (688278.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688278.SH.md"
symbol: "688278.SH"
name: "Xiamen Amoytop Biotech Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T16:47:18.937Z"
locales:
  - [en](https://longbridge.com/en/quote/688278.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688278.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688278.SH.md)
---

# Xiamen Amoytop Biotech Co., Ltd. (688278.SH)

## Company Overview

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.amoytop.com](https://www.amoytop.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: A (0.19)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 29.70% |  |
| Net Profit YoY | 15.06% |  |
| P/B Ratio | 6.55 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 23823418712.48 |  |
| Revenue | 3826808777.14 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 31.78% | A |
| Profit Margin | 26.53% | A |
| Gross Margin | 89.45% | A |
| Revenue YoY | 29.70% | A |
| Net Profit YoY | 15.06% | C |
| Total Assets YoY | 40.40% | A |
| Net Assets YoY | 32.05% | A |
| Cash Flow Margin | 64.82% | C |
| OCF YoY | 29.70% | A |
| Turnover | 1.00 | A |
| Gearing Ratio | 18.66% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Xiamen Amoytop Biotech Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "29.70%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "15.06%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.55",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "23823418712.48",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3826808777.14",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "31.78%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "26.53%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "89.45%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "29.70%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "15.06%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "40.40%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "32.05%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "64.82%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "29.70%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.00",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "18.66%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 23.32 | 5/81 | 35.95 | 33.47 | 30.28 |
| PB | 6.51 | 59/81 | 12.27 | 11.08 | 9.29 |
| PS (TTM) | 6.19 | 30/81 | 10.57 | 9.80 | 8.51 |
| Dividend Yield | 0.00% | - | 0.89% | 0.81% | 0.74% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-17T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 57.90 |
| Highest Target | 76.00 |
| Lowest Target | 76.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688278.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688278.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688278.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688278.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**